Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: Are We Doing Enough?
Authors:
- 23 September 2025
- journal article
- Published by American Diabetes Association in Diabetes Spectrum
- Vol. 38 (4) , 496-501
Abstract
OBJECTIVE: Patients with type 2 diabetes are at an elevated risk for metabolic dysfunction–associated steatotic liver disease and advanced liver fibrosis. Multiple professional societies recommend initiating screening with a fibrosis-4 (FIB-4) index score calculation. This study aimed to evaluate the frequency of laboratory assessments necessary for FIB-4 score calculation in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A retrospective analysis of de-identified electronic medical records from 337,094 patients aged 40–75 years with type 2 diabetes was conducted to evaluate the completion rate of FIB-4 scoring and adherence to other recommended measurements and medications, including urinary albumin measurement and statin use. RESULTS: Only 33% of patients with type 2 diabetes had all necessary components for FIB-4 score calculation, although this rate increased significantly over time (odds ratio 2.51, 95% CI 2.44–2.58) in the period from 2020 to April 2024 compared with 2010–2014. Urinary albumin measurements also increased but remained low at 13% during the period from 2020 to April 2024. Prescriptions for statin and newer antihyperglycemic medications significantly increased. CONCLUSION: Our findings indicate that, although testing frequency for liver health in patients with type 2 diabetes is gradually increasing, substantial gaps in clinical practice persist.Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 DiabetesJAMA Network Open, 2024
- Surveillance of the liver in type 2 diabetes: important but unfeasible?Diabetologia, 2024
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver FibrosisNew England Journal of Medicine, 2024
- Implementation of a liver health check in people with type 2 diabetesThe Lancet Gastroenterology & Hepatology, 2023
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver diseaseHepatology, 2023
- American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical SettingsEndocrine Practice, 2022
- Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018New England Journal of Medicine, 2021
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2021
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisHepatology, 2017
- Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database AnalysesAmerican Journal of Epidemiology, 2015